MedPath

A Randomized Controlled Trial of Behavioral Activation and Treatment As Usual in the Acute Treatments of Adults with Major Depressive Disorder.

Phase 2
Conditions
Depressive episode
Major Depressive Disorder.
Registration Number
IRCT138807192573N1
Lead Sponsor
Medical university of Kurdistan and Maastricht University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Inclusion criteria : diagnosis of major depression according to the SCID-I, severity above 19 on the BDI and 13 on the HRSD, age 18-70, written consent to participate with the study.
Exclusion criteria : if they have a life time diagnosis of bipolar disorder, organic brain syndrome, psychosis or mental retardation. Additional exclusion criteria are: substantial and imminent suicide risk; a current (e.g., within the past six months) or primary diagnosis of alcohol or drug abuse or dependence or a positive toxicology screen; a primary diagnosis of panic disorder, obsessive-compulsive disorder, psychogenic pain disorder, anorexia, or bulimia. In addition, participants who did not respond favorably within the preceeding year to medication will be excluded. Participants who have unstable medical condition and using any medication that would complicate the administration of antidepressant medication (medication in my study), or have a known allergy to medication in this study will be excluded. Moreover, women who are pregnant or maybe want to be pregnant will be excluded. Lastly, participants have to able to read and understand the questionnaires and interviews used in the study.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Treatment of major depressive disorder. Timepoint: Before intervention, in the middle of Intervention (45 days after starting treatment) and after treament ( after 3 months treatment duration).). Method of measurement: In BA, by BDI-II and In TAU, HRSD is used.
Secondary Outcome Measures
NameTimeMethod
Prevention and relapse of major depressive disorder. Timepoint: One year after termination of the treatment. Method of measurement: In BA, by BDI-II and In TAU, HRSD is used.
© Copyright 2025. All Rights Reserved by MedPath